Salesforce (NYSE:CRM) shares have lagged behind peers in recent years, raising questions about the company's AI strategy.

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

How $2,670 split across three durable high-yield stocks can generate $300 in annual dividends without risky payouts.

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and ...

GSK (GSK) and other leading drugmakers plans to raise prices of as many as 350 medicines next year, with a median hike of ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Goldman Sachs reported a 1.21 percent return for the Tactical Tilt Overlay Fund in a strong third quarter. Review these ...

Stock futures were marginally lower early December 29, as traders grabbed profits at record index levels and exited prominent ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer today and set a price target of $30.00. According to TipRanks, Scala is a 4-star analyst with an average return of 11.3% and a 64.82% ...

Nvidia has discussed boosting H200 GPU production with TSMC as Chinese orders reach about 2 million units, far exceeding ...

Six-time IndyCar champion Scott Dixon is now Sir Scott Dixon after receiving a knighthood in New Zealand’s New Year honors ...